ResearchSafe

PE 22-28 TREK-1 blocker, anyone following the preclinical antidepressant research

Posted by student748 in Research & News - 1 points, 2 comments.

For what it is worth i keep coming back to the PE 22-28 profile page (/peptides/pe-22-28) and wondering if anyone here is actually tracking where this stuff is at in real research terms. The mechanism sounds pretty interesting to me, selective TREK-1 potassium channel blockade leading to faster synaptogenesis and neurogenesis than SSRIs in animal models. That is a big claim though and i keep reminding myself it is all preclinical still.

What gets my attention is the speed angle. If something could support neuroplasticity without the weeks-long lag you get with conventional approaches, that would be huge for people who are really stuck. But the flip side is there is zero established human dosing and no safety data in people. That makes me pretty nervous about anyone self-experimenting with it right now.

Has anyone seen any movement toward actual human trials? Or is this still firmly in the "interesting but years away" bucket? Keen to hear if anyone here has dug deeper into the spadin derivation and whether the improved half-life actually means anything practical yet.

Comments

  • labrat_vik: I've been keeping an eye on this one off and on and honestly it's still firmly in the preclinical bucket as far as I can tell, I haven't seen any human trial registrations pop up which tells you a lot about where it actually stands. The TREK-1 mechanism is genuinely interesting from a pharmacology angle, the whole spadin lineage going back to sort of a derivative of the sortilin propeptide, and PE 22-28 being a shortened analog with better stability, that's elegant work. But elegant preclinical
  • student748: Chur for confirming that, kinda what i expected but good to hear from someone else tracking it. The spadin lineage bit is interesting, i didnt realise PE 22-28 was a shortened analog of that, explains the stability claims a bit better. For what it is worth the "elegant preclinical work is a dime a dozen" line is pretty much exactly where i land on it too. Have you seen any rodent-to-human translational concerns specific to TREK-1 channel distribution, or is it more just the general preclinical g

Community discussion - research and educational context only. Not medical advice.